Protein Targets on GLP-1 Medications: How Much You Need and Why It Matters

What daily protein target applies on a GLP-1 drug?

Two sources land on the same range. Shorter-term studies found that higher-protein weight-loss diets preserved more lean mass than lower-protein diets. The review suggests 1.2 to 1.6 g per kg per day, potentially including about 25 to 30 g per meal, as a useful range [1]. A 2026 review focused on GLP-1 and dual GIP/GLP-1 therapy proposes at least 1.2 g per kg per day, up to 1.6 g per kg in adults without chronic kidney disease, with meal targets of about 0.3 to 0.4 g per kg and about 2.5 to 3 g of leucine [2].

At 100 kg, that is 120 to 160 g of protein a day, and 30 to 40 g per meal at the 0.3 to 0.4 g per kg meal target [1][2].

These figures do not come from the drug labels. The Wegovy and Foundayo labels cover dosing, adverse reactions, drug interactions and the boxed warning about rodent thyroid C-cell tumors [6][7]. The protein numbers come from nutrition research in weight loss and aging, applied to people whose appetite is pharmacologically reduced [1][5][2].

Why appetite suppression changes protein intake

GLP-1 receptor agonists produce weight loss primarily by suppressing appetite and lowering how much people eat [2]. The loss is large. In STEP 1, 1,961 adults without diabetes lost a mean 14.9% of body weight on semaglutide 2.4 mg weekly versus 2.4% on placebo at 68 weeks [8]. In SURMOUNT-1, 2,539 adults lost 20.9% on tirzepatide 15 mg versus 3.1% on placebo at 72 weeks [9].

The EASO, EFAD and ECPO consensus statement notes that reduced appetite, rapid weight loss, gastrointestinal adverse effects and changed eating behaviour may create nutritional, functional or psychological risks in some people [3]. Randomized trials with body-composition substudies show a clinically relevant reduction in absolute lean mass alongside the fat loss [2]. In weight-loss research, higher-protein energy-restriction diets preserved more lean mass than lower-protein energy-restriction diets [1].

Is there a point where more protein stops helping?

Yes, roughly. A meta-analysis of 49 randomized trials with 1,863 participants found that protein supplementation increased gains in fat-free mass during resistance training, and that total intakes above about 1.62 g per kg per day added nothing further to those gains in healthy adults [4]. The same analysis found the effect of protein supplementation was smaller with increasing age [4].

Does the target change with age?

The PROT-AGE position paper covers people over 65. It recommends an average intake of at least 1.0 to 1.2 g per kg per day to help maintain and regain lean body mass and function, at least 1.2 g per kg for those who are exercising or otherwise active, and 1.2 to 1.5 g per kg for most older adults with acute or chronic disease [5]. Its stated exception is severe kidney disease: people with an eGFR below 30 mL/min/1.73 m² who are not on dialysis may need to limit protein [5].

How should protein be spread across the day?

The per-meal figures are about 25 to 30 g [1], or 0.3 to 0.4 g per kg [2]. Six healthy young men performed leg resistance exercise and then drank 0, 5, 10, 20 or 40 g of whole egg protein; muscle protein synthesis rose with dose and was maximally stimulated at 20 g, with 40 g producing no further response [10]. This small experiment in young men does not establish a per-meal minimum for people taking GLP-1 medications [10].

In one small study, taking protein immediately before or immediately after exercise produced similar results. Twenty-one resistance-trained men took 25 g of protein either immediately before or immediately after each resistance session, three sessions a week for 10 weeks, and strength, muscle size and body composition changes were similar in both groups [11].

Does resistance training change the target?

Protein is not a substitute for training. The EASO, EFAD and ECPO consensus statement names adequate protein intake and progressive resistance exercise as the pragmatic approaches that could help preserve fat-free mass and physical function during weight loss on incretin-based therapy [3]. That is a consensus recommendation built from the available evidence, not the result of a single trial.

What the labels say to expect while you are eating less

On the Wegovy 2.4 mg label, adverse reactions over 68 weeks were nausea 44% versus 16% on placebo, diarrhea 30% versus 16%, vomiting 24% versus 6% and constipation 24% versus 11% [6]. On the Foundayo 17.2 mg label, over 72 weeks, nausea was 35% versus 10%, vomiting 24% versus 4%, constipation 24% versus 9% and diarrhea 25% versus 11% [7]. The Wegovy label notes that rates from different trials cannot be directly compared [6]. The Foundayo label states that nausea, vomiting and diarrhea were more frequent during dose escalation and decreased over time [7].

Both labels warn that nausea, vomiting or diarrhea can lead to dehydration and acute kidney injury [6][7]. Each label tells prescribers to monitor renal function in patients reporting reactions that could lead to volume depletion [6][7].